Mohamed Mahmoud Kamel, Takyi-Williams John, Baudot Bertrand, Grobler Anne
QuantiLAB, BioPark Mauritius, Phoenix, Mauritius.
DST/NWU Preclinical Drug Development Platform (PCDDP), North-West University, Potchefstroom, South Africa.
Eur J Pharm Sci. 2021 Apr 1;159:105705. doi: 10.1016/j.ejps.2021.105705. Epub 2021 Jan 9.
The resurgence of Cannabis therapeutic discoveries have led to the need for sensitive and selective analytical methods for the detection of cannabinoids and their metabolites in biological matrices. High resolution mass spectrometry (HRMS) enables good sensitivity and provides more selectivity due to its accurate mass measurement of the targeted compounds. The aim of this study was to develop and validate a sensitive liquid chromatography high resolution mass spectrometry (LC-HRMS) method for the quantitative analysis of cannabidiol (CBD), cannabinol (CBN), Δ-tetrahydrocannabinol (Δ-THC) and its major metabolites 11-Hydroxy-Δ-THC and 11-Nor-9-carboxy-Δ-THC in human plasma. The method utilized a simple liquid-liquid extraction of the cannabinoids from plasma samples followed by an isocratic chromatographic separation and detection by ESI-HRMS Q-Exactive plus platform. The lower limit of quantification (LLOQ) was 0.2 ng/ mL for the targeted cannabinoids and its metabolites with sample volume of 0.5 mL plasma. The method was linear from 0.2 to 100.0 ng/mL with an average correlation coefficient of >0.995 using weighted (1/x) linear least-squares regression. No significant carry-over was noticed for all analytes and the extraction recovery ranged from 60.4 % to 85.4 %. Dilution results indicated no influence on the accuracy of analysis. The method's intra-day and inter-day precision (CV %) ranged from 2.90 to 10.80 % and accuracy within -0.9 to 7.0 from nominal. Matrix effect ranged from 1.1 % to 49.8 %. The analytes were stable in the autosampler for 6 and 12 h, respectively. This method was sensitive and can be applicable to cannabinoids pharmacokinetics study.
大麻治疗用途新发现的不断涌现,使得需要有灵敏且具选择性的分析方法来检测生物基质中的大麻素及其代谢物。高分辨率质谱法(HRMS)灵敏度高,因其能对目标化合物进行精确质量测量,所以选择性更强。本研究旨在开发并验证一种灵敏的液相色谱-高分辨率质谱法(LC-HRMS),用于定量分析人血浆中的大麻二酚(CBD)、大麻酚(CBN)、Δ-四氢大麻酚(Δ-THC)及其主要代谢物11-羟基-Δ-THC和11-去甲-9-羧基-Δ-THC。该方法采用简单的液-液萃取从血浆样品中提取大麻素,随后进行等度色谱分离,并通过电喷雾电离-高分辨率质谱Q-Exactive plus平台进行检测。对于目标大麻素及其代谢物,当血浆样品体积为0.5 mL时,定量下限(LLOQ)为0.2 ng/mL。该方法在0.2至100.0 ng/mL范围内呈线性,采用加权(1/x)线性最小二乘法回归时,平均相关系数>0.995。所有分析物均未发现明显的残留,萃取回收率在60.4%至85.4%之间。稀释结果表明对分析准确性无影响。该方法的日内和日间精密度(CV%)在2.90%至10.80%之间,准确度在标称值的-0.9%至7.0%之间。基质效应在1.1%至49.8%之间。分析物在自动进样器中分别稳定6小时和12小时。该方法灵敏,可应用于大麻素的药代动力学研究。